DEXCOM INC — Director's Dealing 2016

Jul 14, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2016-07-13

Reporting Person: Balo Andrew K (EVP, Clinical and Regulatory)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-13	Common Stock	M	5000.0	$3.19	Acquired	134979	Direct
2016-07-13	Common Stock	S	5000.0	$80.12	Disposed	129979	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-07-13	Non-Qualified Stock Option (right to buy)	$3.19	M	5000.0	Disposed	2018-12-11	Common Stock (5000)	Direct

Footnotes

F1: On December 11, 2015, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Included in this number are 86,333 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 31,666 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 16,667 of which were granted on March 8, 2014 and shall vest through March 8, 2017.